Selected article for: "alternative vaccine and vaccine vector"
Author: Choi, Kang-Seuk
Title: Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines
  • Document date: 2017_7_26
    • ID: vk59ghjm_13
    Snippet: BHV-1 is a major cause of respiratory tract disease in cattle. A major problem with the current modified live BHV-1 vaccines is their ability to cause latent infection, with the associated risk of subsequent reactivation [19] . As an alternative strategy, Khattar et al. [19] developed a rNDV vaccine (rLaSota/gDFL) expressing the gD of BHV-1. A single intranasal/intratracheal immunization with rLaSota/gDFL (1.5×10 7 PFU/ dose) induced marked muco.....
    Document: BHV-1 is a major cause of respiratory tract disease in cattle. A major problem with the current modified live BHV-1 vaccines is their ability to cause latent infection, with the associated risk of subsequent reactivation [19] . As an alternative strategy, Khattar et al. [19] developed a rNDV vaccine (rLaSota/gDFL) expressing the gD of BHV-1. A single intranasal/intratracheal immunization with rLaSota/gDFL (1.5×10 7 PFU/ dose) induced marked mucosal and systemic antibody responses in calves. Also, intranasal challenge with a high dose of virulent BHV-1 strain Cooper (2×10 7 PFU) led to a marked reduction in viral shedding and more rapid clearance of chal- lenge virus when compared with mock-infected and challenged controls. These results suggest that NDV may have utility as a vaccine vector that can be used to develop a mucosal vaccine against BHV-1 infection of cattle. RVFV, a mosquito-borne bunyavirus that infects ruminants (cattle and sheep), causes severe economic losses to the livestock industry and has a high impact on public health in Africa and the Arabian Peninsula [27] . Currently, a live attenuated vaccine (Smithburn strain) and inactivated RVFV vaccines are available; however, although live attenuated vaccines are highly immunogenic, they are not safe for use in livestock [28, 29] . Inactivated vaccines are safer, but less effective, than live attenuated vaccines and require repeated vaccination [21] . To improve efficacy and safety, Kortekaas et al. [21] developed a NDV-vectored vaccine (NDFL-GnGc) expressing the Gn and Gc glycoproteins of RVFV. Repeat vaccination (two times) of lambs with the NDFL-GnGc vaccine (10 7.3 TCID50/dose) elicited a high titer of neutralizing antibodies specific for RVFV. These results indicate that NDV has potential as a vaccine vector in sheep.

    Search related documents:
    Co phrase search for related documents
    • Africa public health and high impact: 1, 2
    • Africa public health and major cause: 1, 2
    • Africa public health and major problem: 1, 2
    • Africa public health and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • Africa public health and safety efficacy: 1
    • alternative strategy and antibody response: 1, 2, 3
    • alternative strategy and attenuated vaccine: 1, 2
    • alternative strategy and high dose: 1, 2, 3
    • alternative strategy and high impact: 1, 2, 3
    • alternative strategy and live vaccine: 1, 2, 3
    • alternative strategy and major cause: 1
    • alternative strategy and major problem: 1, 2, 3
    • alternative strategy and mucosal vaccine: 1
    • alternative strategy and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
    • alternative strategy and rndv vaccine: 1
    • alternative strategy and safety efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • alternative strategy and safety efficacy improve: 1
    • alternative strategy and sheep cattle: 1
    • alternative strategy and vaccine vector: 1, 2